Brand Name Versus Generics

Preclinical development started with the approval process of the US Food and Drug Administration and this product was safe to use in humans and demonstrated to show "pharmacological activity" that requires further clinical research. (FDA, 2010) Rodents, pigs, and dogs are commonly used to verify the safety and efficacy of laboratory research, as they resemble the human anatomy. (Sivaramakrishan, 2010) The next step in the process is to submit a research drug application form (IND) to the FDA for several reasons.

Review showed changes in brand and generic drug prices. Historically, expensive medicine is a brand name product developed for rare (orphan) condition. Recently, many new medicines for treating common symptoms are dramatically increasing. For example, anti-cancer drugs are used because many medications cost more than $ 100,000 per course. Regarding competition in the pharmaceutical industry, the authors identified market exclusivity (patent protection) as "the most important factor enabling manufacturers to set high drug prices for brand drugs." Depending on the type of exclusivity granted by the government, the exclusive period may last up to 20 years.

There has been long debate over whether generic drugs are as effective and safe as brand pharmaceuticals. Brand drugs are drugs discovered, developed, sold by pharmaceutical companies, and protected by patents. Generic drugs are said to be bioequivalent to brand pharmaceuticals, they do not acquire patents by themselves, they are manufactured and sold only after expiration of the brand pharmaceutical patents. Brand drugs are well-known and reliable but expensive. Common drugs are cheaper than brand drugs, but drugs are not always trusted by people. However, the final decision to select a brand or generic drug is related to the patient and the healthcare team.

· General and brand drug warnings are more common. Some practices have discovered that this is actually setting up an electronic prescription to automatically generate alerts for generic drugs, generating unusually many warnings unless covered by a provider I will. This is an alternative to level alerts, but it should be apparent to all users and that users can make changes themselves. · If the clinician is part of a large interdisciplinary group, in the case of a Health Information Exchange (HIE) available to an integrated distribution network or other provider, an alarm for repeated laboratory and other diagnostic diagnostic tests The results of lesson studies that are becoming increasingly popular These alerts do not receive an indication that the test is being run elsewhere, but when the test results are actually displayed, including the sensitivity of time It is necessary to accept maximum.